Amphipathic Octenyl-Alanine Modified Peptides Mediate Effective siRNA Delivery (2025)
Sequence: H-L{R8}KLAKA{R8}AKLLKA{S8}AKAL-NH2
| Experiment Id | EXP001319 |
|---|---|
| Paper | Amphipathic Octenyl-Alanine Modified Peptides Mediate Effective siRNA Delivery |
| Peptide | hPep3 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | MR30 (N/P 4.3) |
| Formulation Format | peptide/siRNA nanoparticles (electrostatic complexes) |
| Formulation Components | peptide + siRNA in HBG (HEPES-buffered glucose) / cell culture media; complexes at MR30 |
| Size Nm | 80.00 |
| Zeta Mv | 18.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HEK-Luc reporter cells (HEK-293 derived); U87-Luc2 used for uptake/localization (hPep2/hPep3) and silencing validation (hPep3) |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown (luciferase reporter) |
| Output Value | Up to ~75% luciferase knockdown at 200 nM siLuc (24 h, MR30) |
| Output Units | |
| Output Notes | Reporter knockdown quantified after 24 h treatment with hPep/siLuc NPs at MR30; CQ (50 µM, 2 h) increased hPep3-mediated knockdown (~30% improvement), indicating endosomal release limitation. |
| Toxicity Notes | WST-1 assay: viability stayed ~80–100% across 0–200 nM siRNA for all peptides (24 h). |
| Curation Notes |